Krystal Biotech (KRYS) Submits IND Application for KB103, Topical Gene Therapy Candidate for Dystrophic … – StreetInsider.com
|
Krystal Biotech (KRYS) Submits IND Application for KB103, Topical Gene Therapy Candidate for Dystrophic …
StreetInsider.com “KB103 has the potential to become a first-in-class “off-the-shelf” topical gene therapy treatment for DEB. It is the result of an extensive research and preclinical effort by our internal team that included engineering, screening and testing a library … |
